Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanezumab for cancer pain due to bone metastases
CTR20160892Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tanezumab in cancer pain, bone metastases, multiple myeloma (MM), sponsored by Pfizer. Started Jul 2017; status: completed.
02
Drugs
tanezumab
03
Conditions
cancer painbone metastasesmultiple myeloma (MM)
Beyond the preview
Go deeper on CTR20160892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160892.